Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

A Phase II Study of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel with or without Trastuzumab as Primary Systemic Therapy in Locally Advanced Breast Cancer

TADAO SHIMIZU, AKIRA HIRANO, MARI KAMIMURA, KAORU OGURA, NAOMI KIM, OSAMU WATANABE, JUN KINOSHITA, KIYOMI KIMURA, KENJI OGAWA and MARIKO FUJIBAYASHI
Anticancer Research November 2010, 30 (11) 4665-4671;
TADAO SHIMIZU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIRA HIRANO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARI KAMIMURA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAORU OGURA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOMI KIM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OSAMU WATANABE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUN KINOSHITA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIYOMI KIMURA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENJI OGAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ogawasu{at}dnh.twmu.ac.jp
MARIKO FUJIBAYASHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Table I.
  • Table II.
  • Table III.
  • Table IV.
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 30, Issue 11
November 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Phase II Study of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel with or without Trastuzumab as Primary Systemic Therapy in Locally Advanced Breast Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
A Phase II Study of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel with or without Trastuzumab as Primary Systemic Therapy in Locally Advanced Breast Cancer
TADAO SHIMIZU, AKIRA HIRANO, MARI KAMIMURA, KAORU OGURA, NAOMI KIM, OSAMU WATANABE, JUN KINOSHITA, KIYOMI KIMURA, KENJI OGAWA, MARIKO FUJIBAYASHI
Anticancer Research Nov 2010, 30 (11) 4665-4671;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
A Phase II Study of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel with or without Trastuzumab as Primary Systemic Therapy in Locally Advanced Breast Cancer
TADAO SHIMIZU, AKIRA HIRANO, MARI KAMIMURA, KAORU OGURA, NAOMI KIM, OSAMU WATANABE, JUN KINOSHITA, KIYOMI KIMURA, KENJI OGAWA, MARIKO FUJIBAYASHI
Anticancer Research Nov 2010, 30 (11) 4665-4671;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Potential of Inflammatory and Nutritional Markers and Clinicopathological Factors for Prognostic Prediction in Osteosarcoma
  • Diameter of IPDA Is Associated With Maintenance of Hepatic Arterial Blood Flow in DP-CAR
  • Postoperative Changes in Nutritional Status and their Impact on Post-recurrence Prognosis After Pancreatoduodenectomy in Patients With Biliary Tract Carcinoma: An Age-stratified Analysis
Show more Clinical Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire